Talaris Therapeutics, Inc. (TALS): Price and Financial Metrics
GET POWR RATINGS... FREE!
TALS Stock Price Chart Interactive Chart >
TALS Price/Volume Stats
| Current price | $1.34 | 52-week high | $10.56 |
| Prev. close | $1.37 | 52-week low | $0.89 |
| Day low | $1.30 | Volume | 319,100 |
| Day high | $1.41 | Avg. volume | 270,728 |
| 50-day MA | $1.27 | Dividend yield | N/A |
| 200-day MA | $3.89 | Market Cap | 55.91M |
Talaris Therapeutics, Inc. (TALS) Company Bio
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Latest TALS News From Around the Web
Below are the latest news stories about TALARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate TALS as an investment opportunity.
The Talaris Therapeutics Inc. (NASDAQ: TALS) Stock Jumped 13.16% In A Single Month – Are There Any Hopes For A Gain?During the last session, Talaris Therapeutics Inc. (NASDAQ:TALS)’s traded shares were 0.44 million. At the end of the trading day, the stock’s price was $1.29, reflecting an intraday gain of 11.21% or $0.13. The 52-week high for the TALS share is $10.56, that puts it down -718.6 from that peak though still a striking 31.01% … The Talaris Therapeutics Inc. (NASDAQ: TALS) Stock Jumped 13.16% In A Single Month – Are There Any Hopes For A Gain? Read More » |
Talaris Therapeutics Inc. (NASDAQ: TALS) Shares Could Drop Up To -1512.9%In the last trading session, 0.24 million shares of the Talaris Therapeutics Inc. (NASDAQ:TALS) were traded. Most recently the company’s share price was $1.24, and it changed around $0.01 or 1.22% from the last close, which brings the market valuation of the company to $51.10M. TALS currently trades at a discount to its 52-week high … Talaris Therapeutics Inc. (NASDAQ: TALS) Shares Could Drop Up To -1512.9% Read More » |
Have you been able to find a good deal on Talaris Therapeutics Inc.’s shares?The share price of Talaris Therapeutics Inc. (NASDAQ:TALS) fell to $0.94 per share on Wednesday from $0.99. While Talaris Therapeutics Inc. has underperformed by -4.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TALS fell by -93.61%, with highs and lows ranging from $16.63 to $0.97, […] |
We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Talaris Therapeutics Inc. (NASDAQ:TALS) Stock Has Fallen -92.54% YTD, What Do Analysts Anticipate Next?In last trading session, Talaris Therapeutics Inc. (NASDAQ:TALS) saw 0.38 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $48.96M. That closing price of TALS’s stock is … Talaris Therapeutics Inc. (NASDAQ:TALS) Stock Has Fallen -92.54% YTD, What Do Analysts Anticipate Next? Read More » |
TALS Price Returns
| 1-mo | 43.06% |
| 3-mo | -15.72% |
| 6-mo | -69.89% |
| 1-year | -85.11% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 31.37% |
| 2022 | -93.33% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...